Advertisement
Advertisement
BLRX
BioLineRX Ltd
1.71
USDSponsored
-0.06
-3.28%
Nov 06, 15:45 UTC -5
Closed
After-Market
1.55
-0.16
-9.42%
BioLineRX Ltd (BLRX) Earnings
BLRX Earnings Reports
Positive Surprise Ratio
No Data Available for BLRX
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
BioLineRX Ltd earnings per share and revenue
On Aug 31, 2026, BLRX reported earnings of -0.77 USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached 290.00 thousand, compared to an expected --, with a --% difference. The market reacted with a +7.69% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Guardian Pharmacy Services, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.30
Actual
$0.33
Surprise
+7.84%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.02
Actual
$0.06
Surprise
+144.90%
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.89
Actual
$1.96
Surprise
+3.17%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.32
Actual
$0.36
Surprise
+9.16%
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.36
Surprise
-11.15%
Profound Medical Corp. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.18
Actual
-$0.21
Surprise
-11.41%
Akebia Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.03
Actual
-$0.04
Surprise
-6.95%
FAQ
What were BioLineRX Ltd's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, BioLineRX Ltd reported EPS of -$0.77, missing estimates by --, and revenue of $290.00K, -- -- expectations.
How did the market react to BioLineRX Ltd's Q2 2026 earnings?
The stock price moved up 7.69%, changed from $2.60 before the earnings release to $2.80 the day after.
When is BioLineRX Ltd expected to report next?
The next earning report is scheduled for --.
What are the forecasts for BioLineRX Ltd's next earnings report?
Based on --
analysts, BioLineRX Ltd is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.